Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Lactobacillus casei PXN 37 and Improved Quality of Life

Research synthesisLow evidenceModerate effect3 studies · 3 beneficial · 0 neutral · 0 harmful

Across 3 review-level studies, all reported beneficial effects of Lactobacillus casei PXN 37 on quality of life, with effect sizes ranging from small to moderate. The predominant effect size was moderate, observed in two of the three reviews. The most studied populations were colorectal cancer patients undergoing chemotherapy, patients with neurodegenerative diseases, and patients with gastrointestinal diseases. No specific dose range was reported across studies.

  • Studied populations: CRC patients undergoing chemotherapy, patients with neurodegenerative diseases (AD, PD, MS, and MCI), GI patients

Caveats: All three studies are systematic reviews, but none reported statistically significant findings for quality of life specifically, and none provided sample sizes or dose details for Lactobacillus casei PXN 37. The evidence is based on reviews that included this probiotic among others, so the specific contribution of Lactobacillus casei PXN 37 is unclear.

Generated May 10, 2026
3 of 3 papers
Back to top